

**Pentraxin-3 level as a vascular endothelial
marker in newly diagnosed and multi-
transfused patients with Beta-thalassemia
major: relation to oxidative stress**

Thesis

*Submitted for the Partial Fulfillment of Master
Degree in Pediatrics*

By

Hebatallah Saad Mahmoud

M.B.B.Ch., 2013

Faculty of Medicine–Ain Shams University

Under Supervision of

Prof. Dr. Mohsen Saleh ElAlfy

Professor of Pediatrics

Faculty of Medicine – Ain Shams University

Prof. Dr. Amira Abdel Moneam Adly

Professor of Pediatrics

Faculty of Medicine – Ain Shams University

Prof. Dr. Eman Abdel Rahman Ismail

Consultant of Clinical Pathology

Faculty of Medicine – Ain Shams University

Faculty of Medicine - Ain Shams University

2018

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mohsen Saleh ElAlfy**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Amira Abdel Moneam Adly**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I wish to introduce my deep respect and thanks to **Prof. Dr. Eman Abdel Rahman Ismail**, Consultant of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hebatallah Saad Mahmoud

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	vii
Abstract	ix
Introduction	2
Aim of the Work	4
Review of Literature	
Beta Thalassemia	5
Pentraxin Family	45
Patients and Methods	67
Results	79
Discussion	108
Summary	122
Conclusion	126
Recommendations	127
References	128
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Common types of beta-thalassemia and severity	23
Table (2):	Comparison of the 3 leading iron-chelating drugs in the management of Thalassemia.....	37
Table (3):	Relationship between PTX3 and cardiovascular disease among observational clinical studies.....	68
Table (4):	Comparison between β -TM patients and controls as regards demographic data.....	81
Table (5):	Clinical data of the studied β -TM patients.....	82
Table (6):	Laboratory and radiological data of the studied β -TM patients	83
Table (7):	Comparison between β -TM patients and control group as regard MDA, pentraxin-3 and CIMT	84
Table (8):	Comparison between β -TM patients and control as regard MDA, pentraxin-3 and CIMT	86
Table (9):	Clinical data among newly diagnosed and chronic β -TM patients	88
Table (10):	Laboratory and radiological data among newly diagnosed and chronic β -TM patients.....	91
Table (11):	MDA and pentarxin-3 levels in relation to clinical characteristics and iron overload of chronic β -TM patients	97
Table (12):	Correlation between MDA and pentarxin-3 and clinical and laboratory data among newly diagnosed β -TM patients	99
Table (13):	Correlation between MDA and pentarxin-3 and clinical and laboratory data among chronic β -TM patients.....	105

List of Tables (cont...)

Table No.	Title	Page No.
Table (14):	Multivariable linear regression analysis for variables related to increased MDA in newly diagnosed patients with β -thalassemia major.....	109
Table (15):	Multivariable linear regression analysis for variables related to increased MDA in chronic patients with β -thalassemia major	110
Table (16):	Multivariable linear regression analysis for variables related to increased pentraxin-3 in newly diagnosed patients with β -thalassemia major	110
Table (17):	Multivariable linear regression analysis for variables related to increased pentraxin-3 in chronic patients with β -thalassemia major	111

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Geographical distribution of, β -thalassemia around the world.....	6
Figure (2):	The structure of haemoglobin (2 α chains and 2 β chains)	7
Figure (3):	Difference between normal and β -thalassemia ineffective erythropoiesis	10
Figure (4):	Pathophysiology of β -thalassemia	17
Figure (5):	Primary and secondary modifiers of the β thalassemia phenotype	22
Figure (6):	Clinical manifestations of Thalassemia	33
Figure (7):	Effects of PTX3 in cardiovascular diseases	58
Figure (8):	PTX3 as a marker of cardiovascular inflammation.....	66
Figure (9):	MDA levels among patients with β -thalassemia major and healthy controls.....	84
Figure (10):	Pentraxin-3 levels among patients with β -thalassemia major and healthy controls.	85
Figure (11):	CIMT among patients with β -thalassemia major and healthy controls.....	85
Figure (12):	MDA levels among patients with newly diagnosed and chronic β -thalassemia major compared with healthy controls.....	87
Figure (13):	Pentraxin-3 levels among patients with newly diagnosed and chronic β -thalassemia major compared with healthy controls.	87
Figure (14):	Disease duration among newly diagnosed and chronic β -TM patients.	89

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (15):	Transfusion index among newly diagnosed and chronic β -TM patients.....	90
Figure (16):	Type of monochelation therapy among newly diagnosed and chronic β -TM patients.....	90
Figure (17):	Total and direct bilirubin among newly diagnosed and chronic β -TM patients.....	92
Figure (18):	LDH among newly diagnosed and chronic β -TM patients.....	93
Figure (19):	Serum ferritin > or < 2500 μ g/L among newly diagnosed and chronic β -TM patients.....	93
Figure (20):	Ferritin among newly diagnosed and chronic β -TM patients.	94
Figure (21):	ALT among newly diagnosed and chronic β -TM patients.....	94
Figure (22):	Pentraxin-3 levels among newly diagnosed and chronic β -TM patients.....	95
Figure (23):	MDA level among newly diagnosed and chronic β -TM patients.	95
Figure (24):	CIMT among newly diagnosed and chronic β -TM patients.	96
Figure (25):	Pentraxin-3 levels among splenectomized and non-splenectomized chronic β -TM patients.....	98
Figure (26):	Correlation between MDA and HbF among newly diagnosed β -TM patients.....	100

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (27):	Correlation between MDA and indirect bilirubin among newly diagnosed β -TM patients.....	100
Figure (28):	Correlation between MDA and LDH among newly diagnosed β -TM patients.....	101
Figure (29):	Correlation between pentraxin-3 and disease duration among newly diagnosed β -TM patients.....	101
Figure (30):	Correlation between pentraxin-3 and transfusion index among newly diagnosed β -TM patients	102
Figure (31):	Correlation between pentraxin-3 and indirect bilirubin among newly diagnosed β -TM patients.....	102
Figure (32):	Correlation between pentraxin-3 and LDH among newly diagnosed β -TM patients	103
Figure (33):	Correlation between pentraxin-3 and ferritin among newly diagnosed β -TM patients.....	103
Figure (34):	Correlation between pentraxin-3 and CIMT among newly diagnosed β -TM patients.....	104
Figure (35):	Correlation between MDA and total bilirubin among chronic β -TM patients.....	106
Figure (36):	Correlation between pentraxin-3 and disease duration among chronic β -TM patients.....	106

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (37):	Correlation between pentraxin-3 and WBC count among chronic β -TM patients.....	107
Figure (38):	Correlation between pentraxin-3 and LDH among chronic β -TM patients.....	107
Figure (39):	Correlation between pentraxin-3 and ferritin among chronic β -TM patients.	108
Figure (40):	Correlation between pentraxin-3 and CIMT among chronic β -TM patients.....	108

List of Abbreviations

Abb.	Full term
<i>ACS</i>	<i>Acute coronary syndrome</i>
<i>AHSP</i>	<i>α-Hb-Stabilizing Protein</i>
<i>ALT</i>	<i>Alanine aminotransferase</i>
<i>AST</i>	<i>Aspartate aminotransferase</i>
<i>BP</i>	<i>Blood pressure</i>
<i>BP</i>	<i>Blood pressure</i>
<i>C4BP</i>	<i>C4b-binding protein</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CIMT</i>	<i>Carotid intima media thickness</i>
<i>CKD</i>	<i>Chronic kidney disease</i>
<i>CRP</i>	<i>C reactive protein</i>
<i>CTD</i>	<i>Connective tissue disease</i>
<i>cTnI</i>	<i>Cardiac troponin I</i>
<i>DFO</i>	<i>Deferoxamine</i>
<i>DFP</i>	<i>Deferiprone</i>
<i>DFX</i>	<i>Deferasirox.</i>
<i>ECM</i>	<i>Extracellular matrix</i>
<i>ECs</i>	<i>Endothelial cells</i>
<i>ESRD</i>	<i>End stage renal disease</i>
<i>GVHD</i>	<i>Graft-versus-host disease</i>
<i>Hb</i>	<i>Hemoglobin</i>
<i>HPLC</i>	<i>High performance liquid chromatography</i>
<i>HSC</i>	<i>Hemopoietic stem cell</i>
<i>HSPGs</i>	<i>Heparin sulphate proteoglycans</i>
<i>IL-6</i>	<i>Interleukin-6</i>
<i>IMT</i>	<i>Intima-media thickness</i>
<i>IRD</i>	<i>Inflammatory rheumatic disease</i>
<i>LDH</i>	<i>Lactate dehydrogenase</i>
<i>LIC</i>	<i>Liver iron concentration</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>MCH</i>	<i>Mean cell hemoglobin</i>
<i>MCV</i>	<i>Mean cell volume</i>
<i>MDA</i>	<i>Malondialdehyde</i>
<i>MI</i>	<i>Myocardial infarction</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>P5N-I</i>	<i>Pyrimidine-5 nucleotidase-I</i>
<i>PAH</i>	<i>Pulmonary arterial hypertension</i>
<i>PAMPs</i>	<i>Pathogen-associated molecular patterns</i>
<i>ROS</i>	<i>Reactive Oxygen Species</i>
<i>SMCs</i>	<i>Smooth muscle cells</i>
<i>TBARS</i>	<i>Thiobarbituric Acid Reactive Substances</i>
<i>TGF-β</i>	<i>Transforming growth factor-β</i>
<i>TLR</i>	<i>Toll-like receptors</i>
<i>TNF-α</i>	<i>Tumor necrosis factor</i>
<i>UAP</i>	<i>Unstable angina pectoris</i>
<i>WBC</i>	<i>White blood cells</i>
<i>β</i>	<i>Beta</i>

Abstract

Background: Vascular endothelial damage starts at an early age in β -thalassemia patients and leads to serious cardiovascular diseases in further years. Pentraxin 3 (PTX-3) can be an indicator of vascular endothelial damage occurring with oxidative stress. **Aim:** To test the hypothesis that vascular endothelial dysfunction could occur in newly diagnosed minimally transfused as well as chronic transfusion-dependent young patients with β -thalassemia major, this study assessed the level of pentraxin-3 as a potential early marker for oxidative stress and assess its relation to markers of hemolysis, iron overload, lipid peroxidation as an index of oxidative stress and subclinical atherosclerosis. **Methods:** Sixty β -TM patients (30 newly diagnosed cases and 30 chronic transfusion dependent ones) without symptoms of heart disease were compared to 30 healthy controls and studied stressing on splenectomy, transfusion history, chelation therapy and mean serum ferritin in last year prior to the study. PTX-3 levels were measured by enzyme linked immunosorbent assay (ELISA) and MDA was assessed by measuring the production of Thiobarbituric Acid Reactive Substances (TBARS). Carotid intima media thickness (CIMT) was measured using Doppler ultrasound. **Results:** Serum MDA, PTX-3 and CIMT were significantly higher in all the studied β -TM patients than the control group ($p<0.05$). MDA and PTX-3 levels were significantly higher in both newly diagnosed and chronic β -TM patients compared with healthy controls with the highest levels found among chronic transfusion-dependent patients ($p<0.05$). CIMT was significantly higher in chronic transfusion-dependent β -TM patients compared with newly diagnosed and healthy controls ($p<0.05$) while no significant difference between the latter two groups ($p>0.05$). Comparison between the clinical data of newly diagnosed and chronic β -TM patients revealed significantly lower blood pressure, disease duration and transfusion index among newly diagnosed patients. The incidence of splenectomy and hepatitis C was higher among chronic β -TM patients. As regard laboratory and radiological data, it was found that bilirubin, liver enzymes, LDH, ferritin, MDA, PTX-3, and CIMT were significantly higher among chronic TM patients compared with newly diagnosed ones while other variables including blood counts were comparable between both groups. Pentarxin-3 levels were significantly elevated in splenectomized patients ($p=0.047$). Chronic β -TM patients with good compliance to chelation had lower pentarxin-3 levels than non-compliant patients ($p=0.036$). Both MDA and pentraxin-3 were positively correlated.

Significant correlations were found between pentraxin-3 and disease duration, transfusion index, total and indirect bilirubin, LDH and serum ferritin as well as CIMT among newly diagnosed β -TM patients. As regards chronic transfusion-dependent β -TM patients, significant correlations were found between pentarxin-3 levels and disease duration, WBC count, LDH, ferritin and CIMT. Multivariable linear regression analysis revealed that LDH, serum ferritin, MDA and CIMT were the significant independent variables related to increased pentraxin-3 levels in newly diagnosed or chronic patients with β -TM. **Conclusion:** We suggest that oxidative stress starts early in pediatric patients with β -TM even in newly diagnosed ones as defined by high levels of PTX-3 and MDA. This process aggravates in chronic transfusion-dependent patients. PTX-3 is a promising marker of oxidative stress in β -TM patients. The positive correlation between CIMT and PTX-3 suggests that it could be used as a marker of vascular dysfunction and subclinical atherosclerosis in β -TM patients. Thus, it could be useful for screening of patients at risk of cardiac complications later in adult life because this alteration occurs in early stage subclinical disease. Good selection of chelation therapy based on the patients' compliance, iron overload status is needed in order to decrease oxidative stress and the incidence of endothelial dysfunction among β -TM patients and consequently, lower PTX-3 levels.

INTRODUCTION

β -thalassemia is an inherited hemoglobin disorder caused by the impaired synthesis of the β -globin chain, resulting in chronic hemolytic anemia (*Higgs et al., 2001*). Iron overloading is a prominent feature in hemolytic anemia as β -thalassemia major owing to hemolysis of impaired erythrocytes as well as increased iron intestinal absorption and erythrocyte transfusion. This results in excessive free iron that represents an oxidative stress to the cells especially vascular endothelial cells. Vascular endothelial damage has a great impact on cardiovascular system with consequent diseases. This starts at an early age in thalassemia patients and leads to serious cardiovascular diseases in further years (*Veerapol et al., 2008*).

All of the newly diagnosed thalassemia major at one year later become transfusion dependent thalassemia major patients with ferritin level that keep up increasing (*Hamizah et al., 2017*).

It has been demonstrated that an increase in lipid peroxidation products such as malondialdehyde (MDA) as a result of oxidative stress is related to the occurrence of atherogenic vascular complications in thalassemia patients (*Esposito et al., 2003; Amer and Fibach, 2005*). In addition, the increased iron load has an impact on the thrombotic response to arterial injury, vascular production of reactive

oxygen species, and endothelium-dependent vasoreactivity (*Kukongviriyapan et al., 2008*).

Therefore, the assessment of endothelial functional impairment is a useful prognostic tool for monitoring cardiovascular diseases (*Esposito et al., 2003; Amer and Fibach, 2005*). It has been shown that one of the markers of vascular endothelial damage is pentraxin 3 (PTX-3) protein (*Verma et al., 2003; Mantovani et al., 2003*). PTX-3, the prototype of long pentraxins, is a discovered marker of the acute-phase inflammatory response, and plays an important role in innate immunity (*Bottazzi et al., 2006; Garlanda et al., 2005*). Similar to C reactive protein (CRP), PTX3 belongs to the PTX protein family (*Hirschfield and Pepys, 2003*). Unlike CRP, which is produced in the liver in response to interleukin-6 (IL-6), PTX3 is mainly produced at extrahepatic sites; endothelial cells, smooth muscle cells, mononuclear phagocytes, and dendritic cells in response to the inflammation and oxidative stress (*Introna et al., 1996*).

It is suggested that PTX-3 increases in response to oxidant stress and can be used as an early diagnostic marker for inflammation. PTX3 is a sensitive and specific biomarker for the diagnosis of cardiovascular diseases such as acute coronary syndrome (ACS) (*Kume and Mitsuoka, 2011*) and also in coronary artery disease patients with inflammatory rheumatic disease (IRD) (*Hollan et al., 2010*). On this basis, PTX-3 can be an indicator of vascular endothelial damage occurring with